logo-loader

Shield Therapeutics remain optimistic about US commercialisation of Accrufer in the US

Published: 12:20 15 Jan 2021 GMT

Shield Therapeutics PLC (LON:STX) Chief Executive Tim Watts joins Proactive London's Katie Pilbeam to discuss their financial and operational update.

Watts highlights the European sales volumes of its breakthrough iron deficiency drug Feraccru which grew by 70% year-on-year.

He concentrates on the discussions that are ongoing with potential US out-licensing partners for Accrufer in the States (Feraccru).

Shield Therapeutics' pricing will be "key metric" - Proactive Research Analyst

Proactive Research Analyst Robin Davison speaks to Thomas Warner after publishing a new research note on iron defiency-focused commercial-stage specialty pharmaceutical company Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) Davison gives an overview of what readers can expect from the note,...

on 3/10/23